Q32 Bio Inc. — Director's Dealing 2018

Apr 4, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-04-02

Reporting Person: PARMAR KUSH (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-02	Common Stock	C	5392037	$0.00	Acquired	6722076	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-02	Series A Preferred Stock	$	C	4204502	Disposed		Common Stock (4204502)	Indirect
2018-04-02	Series B Preferred Stock	$	C	1187535	Disposed		Common Stock (1187535)	Indirect

Footnotes

F1: Following the transactions reported herein, includes 1,276,838 shares of common stock held of record by 5AM Ventures IV, L.P. ("Ventures IV") and 53,201 shares of common stock held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV").

F2: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein.

F3: The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.